Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,573
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
stocks
Nvidia: Back in business in China; Raising fair value estimate
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,890.80 | 74.40 | 0.84% |
CAC 40 | 7,822.00 | 99.91 | 1.29% |
DAX 40 | 24,370.93 | 361.55 | 1.51% |
Dow JONES (US) | 44,393.38 | 138.60 | 0.31% |
FTSE 100 | 8,972.64 | 46.09 | 0.52% |
HKSE | 24,498.95 | 18.81 | -0.08% |
NASDAQ | 20,891.01 | 160.52 | 0.77% |
Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
S&P 500 | 6,289.02 | 25.32 | 0.40% |
S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
SSE Composite Index | 3,516.83 | 13.05 | 0.37% |